Viking Therapeutics, Inc.
Company Stats
- Market Cap
- $3.8B
- as of Sep 30, 2026
- Shares Outstanding
- 116.7M
- Free Float
- 91.0%
Income Statement
- Revenue
- $0
- Operating Income
- -$393.3M
- Net Income
- -$359.6M
Balance Sheet
- Cash & Equivalents
- $165.8M
Returns & Capital
- SBC, 3Y Avg
- $29.1M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $0 | — | — |
| FY2024 | $0 | — | — |
| FY2023 | $0 | — | — |
| FY2022 | $0 | — | — |
| FY2021 | $0 | — | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 16, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Viking’s GLP-1/GIP agonist advances through Phase 3 development
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
September 23, 2026
Drug Pipeline
Viking’s GLP-1/GIP agonist advances through Phase 3 development
September 23, 2026
Drug Pipeline
Lilly and Novo set the backdrop for a changing obesity pipeline
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground